A Phase 1 Study of REM-422 in People With Adenoid Cystic Cancer

Full Title

A Phase 1/2, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent, metastatic, or unresectable adenoid cystic carcinoma

Purpose

Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.

REM-422 lowers the amount of the MYB protein. By reducing MYB levels, REM-422 may slow or stop the growth of your cancer. REM-422 is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Alan Ho’s office at 646-541-7062.